- Home
- RCUS
as 07-26-2024 4:00pm EST
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 1.4B | IPO Year: | 2018 |
| Target Price: | $39.30 | AVG Volume (30 days): | 577.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.95 - $25.47 | Next Earning Date: | 08-05-2024 |
| Revenue: | $237,000,000 | Revenue Growth: | 99.16% |
| Revenue Growth (this year): | 83.21% | Revenue Growth (next year): | -13.76% |
Stock Insider Trading Activity of Arcus Biosciences Inc. (RCUS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jarrett Jennifer | RCUS | Chief Operating Officer | Mar 27 '24 | Sell | $17.55 | 11,551 | $202,720.05 | 215,253 | SEC Form 4 |
| Jarrett Jennifer | RCUS | Chief Operating Officer | Mar 18 '24 | Sell | $17.84 | 12,153 | $216,809.52 | 228,100 | SEC Form 4 |
| Jarrett Jennifer | RCUS | Chief Operating Officer | Mar 18 '24 | Sell | $18.62 | 1,296 | $24,131.52 | 226,804 | SEC Form 4 |
| Jarrett Jennifer | RCUS | Chief Operating Officer | Feb 26 '24 | Sell | $20.07 | 24,555 | $492,818.85 | 274,323 | SEC Form 4 |
| Jarrett Jennifer | RCUS | Chief Operating Officer | Feb 26 '24 | Sell | $20.11 | 34,070 | $685,147.70 | 240,253 | SEC Form 4 |
| Jaen Juan C. | RCUS | President | Feb 26 '24 | Sell | $20.06 | 3,900 | $78,234.00 | 1,211,365 | SEC Form 4 |
| Jaen Juan C. | RCUS | President | Feb 26 '24 | Sell | $20.10 | 23,132 | $464,953.20 | 1,188,233 | SEC Form 4 |
| Jaen Juan C. | RCUS | President | Jan 2 '24 | Sell | $20.09 | 6,975 | $140,127.75 | 1,215,265 | SEC Form 4 |
| Goeltz II Robert C. | RCUS | Chief Financial Officer | Jan 2 '24 | Sell | $20.00 | 2,004 | $40,080.00 | 51,831 | SEC Form 4 |
| Jarrett Jennifer | RCUS | Chief Operating Officer | Dec 22 '23 | Sell | $17.76 | 21,521 | $382,212.96 | 258,878 | SEC Form 4 |
| Azoy Alexander | RCUS | Chief Accounting Officer | Dec 1 '23 | Sell | $14.95 | 282 | $4,215.90 | 11,596 | SEC Form 4 |
Latest Arcus Biosciences Inc. News
RCUS Breaking Stock News: Dive into RCUS Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update
Argus Research
3 days ago
RCUS: Rating increased to a HOLD
Argus Research
10 days ago
RCUS: Raising target price to $13.00
Argus Research
17 days ago
RCUS: Lowering target price to $11.00
Pharmaceutical Technology
18 days ago
Taiho exercises option for Arcus Biosciences’ quemliclustat in Asia
MT Newswires
18 days ago
Arcus Biosciences Says Taiho Has Exercised Option for Exclusive License to Quemliclustat in Japan
Business Wire
18 days ago
Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia
MT Newswires
21 days ago
iTeos, Arcus Shares Drop After Genentech's Lung Cancer Study Misses Endpoints
Compare RCUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RCUS Arcus Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.